

Sorrento Therapeutics, Inc.
Form 8-K/A
October 07, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K/A
(Amendment No. 2)

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2013

SORRENTO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

000-52228
(Commission
File Number)

33-0344842
IRS Employer
Identification No.)

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K/A

6042 Cornerstone Ct. West, Suite B

San Diego, CA 92121

(Address of principal executive offices)

Registrant's telephone number, including area code: (858) 210-3700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note

On September 11, 2013, Sorrento Therapeutics, Inc. (Sorrento) filed a Current Report on Form 8-K under Item 2.01 (the Initial Report) to report the completion of its acquisition of IgDraSol, Inc. (IgDraSol) on September 9, 2013. On September 30, 2013 Sorrento filed the required financial information by amendment, as permitted by Item 9.01(a)(4) and 9.01(b)(2) to Form 8-K. The purpose of this Current Report on Amendment No. 2 to Form 8-K/A is to re-file the accountants consent to include incorporation by reference to certain registration statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
23.1	Consent of Kelly & Company.
99.1	Audited financial statements of IgDraSol, Inc. as of and for the period ending December 31, 2012.*
99.2	Unaudited financial statements of IgDraSol, Inc. for the six months ending June 30, 2013 and 2012 and the period from May 17, 2012 (inception) through June 30, 2013.*
99.3	Unaudited Pro Forma Condensed Consolidated Financial Information.*

* Previously filed

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.

Date: October 7, 2013

By: /s/ Richard Vincent
Richard Vincent
Chief Financial Officer and Secretary